-
61.发明授权Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions 有权二氢蝶啶酮，其制备方法及其作为药物组合物的用途公开(公告)号：US06861422B2
公开(公告)日：2005-03-01
申请号：US10374876
申请日：2003-02-26
申请人： Matthias Hoffmann , Matthias Grauert , Trixi Brandl , Steffen Breitfelder , Christian Eickmeier , Martin Steegmaier , Gisela Schnapp , Anke Baum , Jens Juergen Quant , Flavio Solca , Florian Colbatzky
发明人： Matthias Hoffmann , Matthias Grauert , Trixi Brandl , Steffen Breitfelder , Christian Eickmeier , Martin Steegmaier , Gisela Schnapp , Anke Baum , Jens Juergen Quant , Flavio Solca , Florian Colbatzky
IPC分类号： A61P35/00 , C07D475/00 , C07D519/00 , C07D487/04 , A61K31/4985
CPC分类号： C07D295/073 , C07D475/00
摘要： The present invention relates to new dihydropteridinones of general formula (I): wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
摘要翻译： 本发明涉及通式（I）的新的二氢蝶啶酮：其中基团L和R 1 -R 5具有权利要求书和说明书中给出的含义，其异构体，制备这些二氢蝶啶的方法和用途 作为药物组合物。
-
62.发明申请Methods of treating diseases or conditions using dihydropteridinone compounds 审中-公开使用二氢蝶啶酮化合物治疗疾病或病症的方法公开(公告)号：US20050014760A1
公开(公告)日：2005-01-20
申请号：US10903807
申请日：2004-07-30
申请人： Matthias Hoffmann , Matthias Grauert , Trixi Brandl , Steffen Breitfelder , Christian Eickmeier , Martin Steegmaier , Gisela Schnapp , Anke Baum , Jens Quant , Flavio Solca , Florian Colbatzky
发明人： Matthias Hoffmann , Matthias Grauert , Trixi Brandl , Steffen Breitfelder , Christian Eickmeier , Martin Steegmaier , Gisela Schnapp , Anke Baum , Jens Quant , Flavio Solca , Florian Colbatzky
IPC分类号： A61P35/00 , C07D475/00 , C07D519/00 , A61K31/525
CPC分类号： C07D295/073 , C07D475/00
摘要： Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R1-R5 have the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.
摘要翻译： 公开了通式（I）的新的二氢蝶啶酮，其中基团L和R 1 -R 5具有权利要求书和说明书中给出的含义，其异构体，制备这些二氢蝶呤的中间体和方法及其用途 药物组合物。
-
公开(公告)号：US06492377B1
公开(公告)日：2002-12-10
申请号：US09559806
申请日：2000-04-26
申请人： Stefan Blech , Adrian Carter , Wolfram Gaida , Matthias Hoffmann , Ulrike Kuefner-Muehl , Christopher John Montague Meade , Gerald Pohl , Werner Kummer , Erich Lehr , Joachim Mierau , Thomas Weiser
发明人： Stefan Blech , Adrian Carter , Wolfram Gaida , Matthias Hoffmann , Ulrike Kuefner-Muehl , Christopher John Montague Meade , Gerald Pohl , Werner Kummer , Erich Lehr , Joachim Mierau , Thomas Weiser
IPC分类号： C07D48714
CPC分类号： C07D487/14
摘要： New imidazotriazolopyrimidine derivatives of the formula Preferred are those compounds wherein: R1 denotes methyl, which is optionally substituted by phenyloxy or pyrrole; or R1 denotes benzyl which is optionally substituted by hydroxy, methoxy, dimethylaminoethoxy or fluorine; or R1 denotes cyclopentyl, furan or phenylethyl; R2 or R3 denote ethyl, n-propyl, allyl or propargyl; R4 or R6 denote hydrogen; and, R5 denotes methyl, n-propyl, tert.butyl, cyclopentyl or norbornenyl. These are adenosine antagonists are are useful for, inter alia, the treatment of senile dementia of the Alzheimer's type.
摘要翻译： 式的新咪唑并三唑并嘧啶衍生物优选的是其中：R 1表示甲基，其任选被苯氧基或吡咯取代; 或R 1表示任选被羟基，甲氧基，二甲基氨基乙氧基或氟取代的苄基; 或R 1表示环戊基，呋喃或苯乙基; R 2或R 3表示乙基，正丙基，烯丙基或炔丙基; R 4或R 6表示氢; R5表示甲基，正丙基，叔丁基，环戊基或降冰片烯基。这些腺苷拮抗剂尤其可用于治疗老年痴呆症的老年痴呆症。
-
公开(公告)号：US4544524A
公开(公告)日：1985-10-01
申请号：US658521
申请日：1984-10-09
申请人： Tiberiu Mizrah , Matthias Hoffmann , Peter Kaser , Klemens Heilig
发明人： Tiberiu Mizrah , Matthias Hoffmann , Peter Kaser , Klemens Heilig
CPC分类号： C04B35/58071 , C04B35/64 , C04B35/65 , C25C3/08 , C04B2235/656
摘要： The solid cathodes built into reduction cells for aluminum production have at least one workface which can be wet by the precipitated metal. The starting materials, which contain titanium, boron and carbon in powder form, are first intimately mixed in such proportions that the sum of the powdered carbon and any carbon extracted from the substrate is in excess with respect to the amount required by the starting materials to form titanium diboride. This mixture is heated under a neutral or reducing atmosphere to 1600.degree.-2200.degree. C. and held for 5-45 min at this temperature. The reaction product containing pores and channels is then heated further, to 2250.degree.-2600.degree. C., and held there for 10-60 min to form a compact titanium diboride/carbon eutectic. Subsequently, the solid cathode is cooled to room temperature.
-
65.发明授权Therapeutic methods employing substituted piperidines which are CCR3 antagonists 有权使用CCR3拮抗剂的取代哌啶的治疗方法公开(公告)号：US08653075B2
公开(公告)日：2014-02-18
申请号：US13596225
申请日：2012-08-28
申请人： Marc Grundl , Horst Dollinger , Riccardo Giovannini , Christoph Hoenke , Matthias Hoffmann , Jan Kriegl , Domnic Martyres , Georg Rast , Peter Seither
发明人： Marc Grundl , Horst Dollinger , Riccardo Giovannini , Christoph Hoenke , Matthias Hoffmann , Jan Kriegl , Domnic Martyres , Georg Rast , Peter Seither
IPC分类号： A61K31/535 , A61K31/445
CPC分类号： C07D401/04 , A61K31/4523 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5355 , A61K31/56 , C07D401/14 , C07D413/04 , C07D413/14 , C07D417/14
摘要： Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明的目的是新的取代的式1化合物，其中A，R 1，R 2，R 3和R 4如描述中所定义。 本发明的另一个目的是提供CCR3的拮抗剂，更具体地说是提供包含药用载体和治疗有效量的至少一种本发明化合物或其药学上可接受的盐的药物组合物。
-
66.发明授权公开(公告)号：US08334378B2
公开(公告)日：2012-12-18
申请号：US12706936
申请日：2010-02-17
申请人： Trixi Brandl , Udo Maier , Matthias Hoffmann , Stefan Scheuerer , Anne T. Joergensen , Alexander Pautsch , Steffen Breitfelder , Matthias Grauert , Christoph Hoenke , Klaus Erb , Michael Pieper , Ingo Pragst
发明人： Trixi Brandl , Udo Maier , Matthias Hoffmann , Stefan Scheuerer , Anne T. Joergensen , Alexander Pautsch , Steffen Breitfelder , Matthias Grauert , Christoph Hoenke , Klaus Erb , Michael Pieper , Ingo Pragst
IPC分类号： C07D417/14 , C07D413/14 , C07D513/04
CPC分类号： C07D513/04
摘要： Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.
摘要翻译： 公开了通式（I）的噻唑基 - 二氢 - 喹唑啉，其中基团R 1至R 4具有权利要求书和说明书中给出的含义，其异构体，以及这些化合物的制备方法及其作为药物组合物的用途。
-
公开(公告)号：US08193188B2
公开(公告)日：2012-06-05
申请号：US12578737
申请日：2009-10-14
IPC分类号： A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495
CPC分类号： C07D471/04
摘要： Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.
摘要翻译： 公开了吡啶二氢吡嗪酮化合物，其制备方法及其作为药物组合物的用途。 根据本发明的化合物对应于通式（I），而基团L，R 1，R 2，R 3，R 4和R 5可以具有权利要求和说明书中给出的含义。
-
公开(公告)号：US08148403B2
公开(公告)日：2012-04-03
申请号：US12446001
申请日：2007-10-25
IPC分类号： A61K31/445 , C07D401/00
CPC分类号： C07D401/14 , C07D401/04 , C07D407/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R1, R2, R3 and D are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明的一个目的是式（1）的新的取代的哌啶基 - 丙烷 - 硫醇，其中R1，R2，R3和D定义如下。 本发明的另一个目的是提供CCR-3的激动剂或拮抗剂或其药学上可接受的盐，更具体地提供药物组合物，其包含药学上可接受的载体和治疗有效量的至少一种本发明的化合物 或其药学上可接受的盐。
-
公开(公告)号：US20100317669A1
公开(公告)日：2010-12-16
申请号：US12446001
申请日：2007-10-25
IPC分类号： A61K31/454 , C07D401/14 , A61K31/4545 , C07D401/04 , A61K31/501 , C07D417/14 , C07D405/14 , C07D409/14 , A61K31/506 , C07D413/14 , A61P9/10 , A61P29/00 , A61P37/08 , A61P7/00 , A61P31/00
CPC分类号： C07D401/14 , C07D401/04 , C07D407/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： One object of the present invention are novel substituted piperidyl-propane-thiols of the formula (1), wherein R1, R2, R3 and D are defined as below. Another object of the present invention is to provide agonists or antagonists of CCR-3, or pharmaceutically acceptable salts thereof, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
摘要翻译： 本发明的一个目的是式（1）的新的取代的哌啶基 - 丙烷 - 硫醇，其中R1，R2，R3和D定义如下。 本发明的另一个目的是提供CCR-3的激动剂或拮抗剂或其药学上可接受的盐，更具体地提供药物组合物，其包含药学上可接受的载体和治疗有效量的至少一种本发明的化合物 或其药学上可接受的盐。
-
70.发明授权Dihydropteridione derivatives, process for their manufacture and their use as medicament 有权二氢丙啶衍生物，其制备方法及其作为药物的用途公开(公告)号：US07723517B2
公开(公告)日：2010-05-25
申请号：US12192478
申请日：2008-08-15
IPC分类号： C07D475/00
CPC分类号： C07D295/155 , C07D487/04 , Y02P20/55
摘要： Disclosed are new dihydropteridinones of the formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings provided herein, the isomers thereof, processes for preparing these dihydropteridinones and their use as pharmaceutical compositions.
摘要翻译： 公开了式（I）的新的二氢蝶啶酮，其中基团L，R 1，R 2，R 3，R 4和R 5具有本文提供的含义，其异构体，制备这些二氢蝶啶烷的方法及其作为药物组合物的用途。
-
-
-
-
-
-
-
-
-
搜索结果
108 条记录 (耗时 0.042 秒)
